Evidence map›Paper›PMID 40713680›Full record

ReviewTranslational neurodegeneration2025

Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.

Chonglei Fu, Xuehui Li, Xiaoxing Liu, Yongbo Zheng, Xiangxian Ma, Bo Zhang, Si Chen, Lingming Hu, Sizhen Su, Xiaokun Wang and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chonglei Fu *Institute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Xuehui Li *Hospital for Skin Diseases, Shandong First Medical University, Jinan, 250021, China.
Xiaoxing Liu *National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, 100191, China.
Yongbo ZhengPeking-Tsinghua Centre for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China.
Xiangxian MaInstitute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Bo ZhangDepartment of Clinical Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Si ChenInstitute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Lingming HuDepartment of Clinical Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Sizhen SuNational Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, 100191, China.
Xiaokun WangNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.
Jie SunPain Medicine Center, Peking University Third Hospital, Beijing, 100191, China.
Qingqing YinDepartment of Geriatric Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250117, China.
Yumei WangDepartment of Clinical Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Xiaolong FuInstitute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Yanping BaoNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.
Yanxue XueNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.
Tao XinInstitute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Lin LuInstitute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. linlu@bjmu.edu.cn.
Guichang ZouDepartment of Clinical Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China. guicz@sdfmu.edu.cn.ORCID http://orcid.org/0009-0007-6688-782X

Funding

Academic Promotion Program of Shandong First Medical University 2023ZL001Excellent Youth Fund Project supported by Shandong Provincial Natural Science Foundation ZR2024YQ040National Natural Science Foundation of China 82241032National Natural Science Foundation of China 82288101National Natural Science Foundation of China 82471444Shandong Postdoctoral Science Foundation SDBX202302023Shandong Postdoctoral Science Foundation SDCX-ZG-202400157Shandong University Youth Innovation Team Development Plan 2023KJ180STI2030-Major Projects 2021ZD0200800Taishan Scholars Program of Shandong Province tsqn202312236Wellcome Trust 202404
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treatments to stop neurodegeneration or promote neuronal regeneration in AD remain elusive. Psychoactive substances as modulators of neurophysiological functions, have received increased attention in research. The main psychoactive agents, such as central nervous system depressants and stimulants, cannabinoids, psychedelics, opioids and ketamine, are being explored for their abilities to enhance learning and cognitive performance and potential neurorestorative functions. In this paper, we review the molecular mechanisms and therapeutic potential of psychoactive substances in AD, in the aim to guide future research directions.

Indexed as

Alzheimer DiseasePsychotropic DrugsAnimalsHumansPsychotropic DrugsAlzheimer's diseaseChallengesMolecular insightsPsychoactive substancesTherapeutic potential

Identifiers

PMID40713680
PMCPMC12291523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.